Bladder cancer diagnosis and recurrence prognosis: Comparison of markers with emphasis on survivin

Clinica Chimica Acta

Volumn 368, Issue 1-2, 2006, Pages 20-32

  Schultz, Iman J ^a   Witjes, J Alfred ^a   Swinkels, Dorine W ^a   de Kok, Jacques B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Diagnosis; Recurrence prediction; Survivin

Indexed keywords

CYTOKERATIN 20; KI 67 ANTIGEN; MESSENGER RNA; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER TEST; CELL CYCLE; CYTOLOGY; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; METHYLATION; MICROANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; CELL SHAPE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33646851954     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.12.036     Document Type: Review

References (148)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
3. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 170 (2003) 226-229
4. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., and Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135-138
5. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
6. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 (2003) 8581-8589
7. Badran A., Yoshida A., Ishikawa K., et al. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 314 (2004) 902-907
8. Mahotka C., Wenzel M., Springer E., Gabbert H.E., and Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59 (1999) 6097-6102
9. Fukuda S., Foster R.G., Porter S.B., and Pelus L.M. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100 (2002) 2463-2471
10. Mahboubi K., Li F., Plescia J., et al. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest 81 (2001) 327-334
11. Grossman D., Kim P.J., Blanc-Brude O.P., et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 108 (2001) 991-999
12. Mirza A., McGuirk M., Hockenberry T.N., et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21 (2002) 2613-2622
13. Suzuki A., Ito T., Kawano H., et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19 (2000) 1346-1353
14. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58 (1998) 5315-5320
15. Jiang X., Wilford C., Duensing S., Munger K., Jones G., and Jones D. Participation of survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J Cell Biochem 83 (2001) 342-354
16. Kanwar J.R., Shen W.P., Kanwar R.K., Berg R.W., and Krissansen G.W. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93 (2001) 1541-1552
17. Li F., Ackermann E.J., Bennett C.F., et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1 (1999) 461-466
18. Olie R.A., Simoes-Wust A.P., Baumann B., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 (2000) 2805-2809
19. Xia C., Xu Z., Yuan X., et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1 (2002) 687-694
20. Kasof G.M., and Gomes B.C. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 276 (2001) 3238-3246
21. Kobayashi K., Hatano M., Otaki M., Ogasawara T., and Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A 96 (1999) 1457-1462
22. O'Connor D.S., Grossman D., Plescia J., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 97 (2000) 13103-13107
23. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., and Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152 (1998) 43-49
24. Velculescu V.E., Madden S.L., Zhang L., et al. Analysis of human transcriptomes. Nat Genet 23 (1999) 387-388
25. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
26. Hirohashi Y., Torigoe T., Maeda A., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8 (2002) 1731-1739
27. Grossman D., McNiff J.M., Li F., and Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113 (1999) 1076-1081
28. Islam A., Kageyama H., Takada N., et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19 (2000) 617-623
29. Hattori M., Sakamoto H., Satoh K., and Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 169 (2001) 155-164
30. Hoffman W.H., Biade S., Zilfou J.T., Chen J., and Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277 (2002) 3247-3257
31. Grabowski P., Kuhnel T., Muhr-Wilkenshoff F., et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88 (2003) 115-119
32. Martinez A., Bellosillo B., Bosch F., et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164 (2004) 501-510
33. Javle M.M., Tan D., Yu J., et al. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 51 (2004) 1653-1657
34. Shinohara E.T., Gonzalez A., Massion P.P., et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 103 (2005) 1685-1692
35. Fields A.C., Cotsonis G., Sexton D., Santoianni R., and Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 17 (2004) 1378-1385
36. Kennedy S.M., O'Driscoll L., Purcell R., et al. Prognostic importance of survivin in breast cancer. Br J Cancer 88 (2003) 1077-1083
37. Okada E., Murai Y., Matsui K., et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163 (2001) 109-116
38. Trieb K., Lehner R., Stulnig T., Sulzbacher I., and Shroyer K.R. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 29 (2003) 379-382
39. Vriesema J.L., Poucki M.H., Kiemeney L.A., and Witjes J.A. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology 56 (2000) 793-797
40. Glas A.S., Roos D., Deutekom M., Zwinderman A.H., Bossuyt P.M., and Kurth K.H. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 169 (2003) 1975-1982
41. Planz B., Jochims E., Deix T., Caspers H.P., Jakse G., and Boecking A. The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 31 (2005) 304-308
42. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-816
43. Eissa S., Swellam M., el Mosallamy H., et al. Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res 23 (2003) 4347-4355
44. Melissourgos N., Kastrinakis N.G., Davilas I., Foukas P., Farmakis A., and Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 62 (2003) 362-367
45. Hautmann S., Toma M., Lorenzo Gomez M.F., et al. ImmunoCyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 46 (2004) 466-471
46. Pfister C., Chautard D., Devonec M., et al. ImmunoCyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 169 (2003) 921-924
47. Lodde M., Mian C., Wiener H., Haitel A., Pycha A., and Marberger M. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology 58 (2001) 362-366
48. Vriesema J.L., Atsma F., Kiemeney L.A., Peelen W.P., Witjes J.A., and Schalken J.A. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58 (2001) 367-371
49. Mian C., Pycha A., Wiener H., Haitel A., Lodde M., and Marberger M. ImmunoCyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161 (1999) 1486-1489
50. Feil G., Zumbragel A., Paulgen-Nelde H.J., et al. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res 23 (2003) 963-967
51. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
52. Shariat S.F., Casella R., Khoddami S.M., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171 (2004) 626-630
53. Shariat S.F., Casella R., Monoski M.A., Sulser T., Gasser T.C., and Lerner S.P. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol 170 (2003) 2244-2247
54. Schroeder G.L., Lorenzo-Gomez M.F., Hautmann S.H., et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 172 (2004) 1123-1126
55. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61 (2003) 109-118
56. Lokeshwar V.B., Obek C., Pham H.T., et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 163 (2000) 348-356
57. Lokeshwar V.B., Schroeder G.L., Selzer M.G., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95 (2002) 61-72
58. Dettlaff-Pokora A., Matuszewski M., and Schlichtholz B. Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer. Cancer Lett 222 (2005) 83-88
59. Sanchini M.A., Bravaccini S., Medri L., et al. Urine telomerase: an important marker in the diagnosis of bladder cancer. Neoplasia 6 (2004) 234-239
60. Erdem E., Dikmen G., Atsu N., Dogan P., and Ozen H. Telomerase activity in diagnosis of bladder cancer. Scand J Urol Nephrol 37 (2003) 205-209
61. de Kok J.B., van Balken M.R., Ruers T.J., Swinkels D.W., and Klein Gunnewiek J.M. Detection of telomerase activity in urine as a tool for noninvasive detection of recurrent bladder tumors is poor and cannot be improved by timing of sampling. Clin Chem 46 (2000) 2014-2015
62. Stoeber K., Swinn R., Prevost A.T., et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 94 (2002) 1071-1079
63. Kageyama S., Isono T., Iwaki H., et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 50 (2004) 857-866
64. Weikert S., Christoph F., Schrader M., Krause H., Miller K., and Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116 (2005) 100-104
65. Bowles L., Bialkowska-Hobrzanska H., Bukala B., Nott L., and Razvi H. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol 11 (2004) 2438-2444
66. Ito H., Kyo S., Kanaya T., et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 4 (1998) 2807-2810
67. Bialkowska-Hobrzanska H., Bowles L., Bukala B., Joseph M.G., Fletcher R., and Razvi H. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma. Mol Diagn 5 (2000) 267-277
68. Neves M., Ciofu C., Larousserie F., et al. Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol 167 (2002) 1276-1281
69. Weikert S., Krause H., Wolff I., et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer (2005)
70. Buchumensky V., Klein A., Zemer R., Kessler O.J., Zimlichman S., and Nissenkorn I. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?. J Urol 160 (1998) 1971-1974
71. Eissa S., Kassim S.K., Labib R.A., et al. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 103 (2005) 1356-1362
72. Siracusano S., Niccolini B., Knez R., et al. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur Urol 47 (2005) 327-333
73. Cassel A., Rahat M.A., Lahat N., Lindenfeld N., Mecz Y., and Stein A. Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J Urol 166 (2001) 841-844
74. Retz M., Lehmann J., Amann E., Wullich B., Roder C., and Stockle M. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol 169 (2003) 86-89
75. Harnden P., Allam A., Joyce A.D., Patel A., Selby P., and Southgate J. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 27 (1995) 169-174
76. Ishiwata S., Takahashi S., Homma Y., et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 57 (2001) 811-815
77. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950-1954
78. Friedrich M.G., Toma M.I., Hellstern A., et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 92 (2003) 911-914
79. Dal Canto M., Bartoletti R., Travaglini F., et al. Molecular urinary sediment analysis in patients with transitional cell bladder carcinoma. Anticancer Res 23 (2003) 5095-5100
80. Schneider A., Borgnat S., Lang H., et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 60 (2000) 4617-4622
81. Amira N., Mourah S., Rozet F., et al. Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer 101 (2002) 293-297
82. Chan M.W., Chan L.W., Tang N.L., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8 (2002) 464-470
83. Dulaimi E., Uzzo R.G., Greenberg R.E., Al Saleem T., and Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10 (2004) 1887-1893
84. Friedrich M.G., Weisenberger D.J., Cheng J.C., et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 10 (2004) 7457-7465
85. Hoque M.O., Lee J., Begum S., et al. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res 63 (2003) 5723-5726
86. Zieger K., Wolf H., Olsen P.R., and Hojgaard K. Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU Int 85 (2000) 824-828
87. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
88. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Palou J., Algaba F., and Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164 (2000) 680-684
89. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Palou J., and Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73-78
90. Holmang S., Hedelin H., Anderstrom C., Holmberg E., Busch C., and Johansson S.L. Recurrence and progression in low grade papillary urothelial tumors. J Urol 162 (1999) 702-707
91. Bol M.G., Baak J.P., Buhr-Wildhagen S., et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 169 (2003) 1291-1294
92. Tosoni I., Wagner U., Sauter G., et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 85 (2000) 48-53
93. Swana H.S., Grossman D., Anthony J.N., Weiss R.M., and Altieri D.C. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341 (1999) 452-453
94. Ku J.H., Kwak C., Lee H.S., Park H.K., Lee E., and Lee S.E. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171 (2004) 631-635
95. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
96. Cordon-Cardo C., Wartinger D., Petrylak D., et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84 (1992) 1251-1256
97. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90 (1998) 1072-1079
98. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007-1013
99. Gontero P., Casetta G., Zitella A., et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 38 (2000) 287-296
100. Santos L.L., Amaro T., Pereira S.A., et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 29 (2003) 74-80
101. Migaldi M., Sgambato A., Garagnani L., et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 6 (2000) 3131-3138
102. Pfister C., Moore L., Allard P., et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5 (1999) 4079-4084
103. Sgambato A., Migaldi M., Faraglia B., et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 59 (1999) 3245-3250
104. Lacoste-Collin L., Gomez-Brouchet A., Escourrou G., Delisle M.B., Levade T., and Uro-Coste E. Expression of p27(Kip1) in bladder cancers: immunohistochemical study and prognostic value in a series of 95 cases. Cancer Lett 186 (2002) 115-120
105. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 122 (2004) 444-452
106. Wagner U., Suess K., Luginbuhl T., et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 188 (1999) 44-50
107. Theodoropoulos V.E., Lazaris A.C., Kastriotis I., et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95 (2005) 425-431
108. Santos L., Amaro T., Costa C., et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 105 (2003) 267-272
109. Pich A., Chiusa L., Formiconi A., et al. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 95 (2002) 784-790
110. Yan Y., Andriole G.L., Humphrey P.A., and Kibel A.S. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer 95 (2002) 1239-1246
111. Oosterhuis J.W., Schapers R.F., Janssen-Heijnen M.L., Smeets A.W., and Pauwels R.P. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 88 (2000) 2598-2605
112. Wu T.T., Chen J.H., Lee Y.H., and Huang J.K. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 163 (2000) 758-760
113. Asakura T., Takano Y., Iki M., et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 158 (1997) 385-388
114. Ramos D., Navarro S., Villamon R., Gil-Salom M., and Llombart-Bosch A. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer 97 (2003) 1876-1883
115. Su J.S., Arima K., Hasegawa M., et al. Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. Int J Urol 11 (2004) 74-82
116. Toma V., Hauri D., Schmid U., et al. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 155 (1999) 1427-1432
117. Yamamoto Y., Matsuyama H., Furuya T., et al. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res 10 (2004) 6449-6455
118. Mizutani Y., Hongo F., Sato N., Ogawa O., Yoshida O., and Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92 (2001) 287-293
119. Mizutani Y., Matsubara H., Yamamoto K., et al. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 101 (2004) 1794-1802
120. de Kok J.B., Roelofs R.W., Giesendorf B.A., et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85 (2005) 154-159
121. Schultz I.J., Kiemeney L.A., Karthaus H.F., et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 50 (2004) 1425-1428
122. Schultz I.J., Kiemeney L.A., Witjes J.A., et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23 (2003) 3327-3331
123. Gazzaniga P., Gradilone A., Giuliani L., et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14 (2003) 85-90
124. Ariel I., Sughayer M., Fellig Y., et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 53 (2000) 320-323
125. Crew J.P., O'Brien T., Bradburn M., et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57 (1997) 5281-5285
126. Hara I., Miyake H., Hara S., Arakawa S., and Kamidono S. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol 165 (2001) 1769-1772
127. Miyake H., Eto H., Arakawa S., Kamidono S., and Hara I. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 167 (2002) 1282-1287
128. Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23 (1999) 18-20
129. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., and Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001) 1265-1268
130. Simoneau M., Larue H., Aboulkassim T.O., Meyer F., Moore L., and Fradet Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 19 (2000) 6317-6323
131. Edwards J., Duncan P., Going J.J., Grigor K.M., Watters A.D., and Bartlett J.M. Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. Br J Cancer 85 (2001) 1894-1899
132. Vaish M., Mandhani A., Mittal R.D., and Mittal B. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol 5 (2005) 2
133. Tada Y., Wada M., Taguchi K., et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62 (2002) 4048-4053
134. Kim E.J., Jeong P., Quan C., et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65 (2005) 70-75
135. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003) 1912-1921
136. Dyrskjot L., Thykjaer T., Kruhoffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33 (2003) 90-96
137. Thykjaer T., Workman C., Kruhoffer M., et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 61 (2001) 2492-2499
138. Sanchez-Carbayo M., Socci N.D., Charytonowicz E., et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62 (2002) 6973-6980
139. Richter J., Wagner U., Kononen J., et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157 (2000) 787-794
140. Simon R., Richter J., Wagner U., et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61 (2001) 4514-4519
141. Nocito A., Bubendorf L., Maria T.E., et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194 (2001) 349-357
142. Iwaki H., Kageyama S., Isono T., et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 95 (2004) 955-961
143. Celis J.E., Celis P., Palsdottir H., et al. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics 1 (2002) 269-279
144. Ohlsson G., Moreira J.M., Gromov P., Sauter G., and Celis J.E. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 4 (2005) 570-581
145. Koed K., Wiuf C., Christensen L.L., et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 65 (2005) 34-45
146. Hoque M.O., Lee C.C., Cairns P., Schoenberg M., and Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 63 (2003) 2216-2222
147. Veltman J.A., Fridlyand J., Pejavar S., et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 63 (2003) 2872-2880
148. Primdahl H., Wikman F.P., von der M.H., Zhou X.G., Wolf H., and Orntoft T.F. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 94 (2002) 216-223